Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24176427 | 0.97 | SLC6A9 (0.38) | SLC6A9 | |
| SCHEMBL26711005 | 0.95 | SLC6A9 (0.40) | SLC6A9 | |
| SCHEMBL24176429 | 0.93 | SLC6A9 (0.39) | SLC6A9 | |
| SCHEMBL12356890 | 0.86 | SLC6A9 (0.35) | SLC6A9 | |
| SCHEMBL23053916 | 0.79 | — | — | |
| SCHEMBL7349132 | 0.79 | — | — | |
| SCHEMBL14279683 | 0.79 | SLC6A9 (0.38) | SLC6A9 | |
| SCHEMBL24176194 | 0.79 | SLC6A9 (0.30) | SLC6A9 | |
| SCHEMBL26745951 | 0.77 | — | — | |
| SCHEMBL24900020 | 0.77 | SLC6A9 (0.35) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024138206-A1 | FLUOROPYRIDOPYRIMIDINE AND FLUOROQUINAZOLINE DERIVATIES AND METHODS OF USE THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024112654-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024040131-A1 | PYRIDOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-9993465-B2 | 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-9890137-B2 | 2-halo-5-alkynyl-pyridyl nicotinic ligands | GEORGETOWN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| US-9586968-B2 | Bicycloamine-substituted-N-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170035743-A1 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof | DUKE UNIVERSITY | 2017-02-09 | — | — | US | disclosed |
| US-20170002008-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | US | disclosed |
| US-9303017-B2 | 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031853-A1 | 2-Halo-5-Alkynyl-Pyridyl Nicotinic Ligands | GEORGETOWN UNIVERSITY (US) | 2016-02-04 | — | — | US | disclosed |
| US-20140378428-A1 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | COQ8A, SQSTM1, QARS1 | SLC6A9 2804/4885 |
| US-20140378428-A1 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof | CHRNA4, CHRNA5, OPRL1 | SLC6A9 3585/4885 |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | SLC6A9 503/4885 |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | SLC6A9 1184/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | SLC6A9 4009/4885 |
| US-20170035743-A1 | 2,5-Disubstituted-Pyridyl Nicotinic Ligands, and Methods of Use Thereof | CHRNA4, CHRNA5, OPRL1 | SLC6A9 3585/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | SLC6A9 3855/4885 |
| US-20160031853-A1 | 2-Halo-5-Alkynyl-Pyridyl Nicotinic Ligands | OPRL1, OPRD1, CHRNA5 | SLC6A9 2458/4885 |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | SLC6A9 3100/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | SLC6A9 2551/4885 |
| US-20170002008-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN1B, CACNA1E, CACNA1B | SLC6A9 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.